Back to top
more

Exact Sciences (EXAS)

(Real Time Quote from BATS)

$70.56 USD

70.56
1,130,010

-0.27 (-0.38%)

Updated Sep 20, 2024 03:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street Analysts Believe Exact Sciences (EXAS) Could Rally 34.33%: Here's is How to Trade

The mean of analysts' price targets for Exact Sciences (EXAS) points to a 34.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EW Stock Dips Following the Divestiture of Critical Care Wing

Edwards completes the sale of its Critical Care operations and announces a $1 billion share repurchase program.

EW Stock to Benefit From Favorable RHEIA Trial Data on TAVI

Edwards' first all-female TAVI Trial demonstrates favorable outcomes for women receiving Edwards valves.

Exact Sciences (EXAS) Up 7.5% Since Last Earnings Report: Can It Continue?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases

QGEN's expanded collaboration with AstraZeneca to focus on developing companion diagnostics beyond oncology.

Boston Scientific's ACURATE Prime Aortic Valve System Wins CE Mark

BSX achieves CE Mark approval for the ACURATE Prime Aortic Valve System, its latest TAVR technology.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx

Illumina's cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted therapies.

Abbott's Core Businesses Thrive Despite Macroeconomic Issues

ABT is particularly gaining from the strong adoption of its market leading systems and demand for testing that takes place in a variety of settings.

Verano Expands U.S. Cannabis Footprint With New Buyouts

This deal helps VRNOF foray into the Virginia market ahead of the Adult Use Program launch and will deepen the company's footprint in Arizona cannabis market.

Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes

PODD marks a major milestone with Omnipod 5 approval for the treatment of type 2 diabetes.

John Blank headshot

What Role Will Macro Data Play, Before the U.S. Election?

In other words, can U.S. macro data trump any U.S election uncertainty?

Does Exact Sciences (EXAS) Have the Potential to Rally 34.13% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 34.1% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches

Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.

Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study

Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.

Why You Should Add Exact Sciences (EXAS) to Your Portfolio

Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.

The Zacks Analyst Blog Highlights Nomura Research Institute, Manhattan Associates and Exact Sciences

Nomura Research Institute, Manhattan Associates and Exact Sciences are part of the Zacks top Analyst Blog.

John Blank headshot

Volatility Stays with Markets: Global Week Ahead

Investors should have learned by now that there's no such thing as a "quiet" summer in the markets. A year ago, bond yields rose sharply on worries about the U.S. fiscal outlook. The summer before, inflation and rate hike fears jolted markets.

Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top

Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.

Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates

Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates. The company lowers revenue guidance for 2024. Stock falls.

Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top

Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.